|Bid||5,650.00 x 20000|
|Ask||5,850.00 x 3500|
|Day's Range||5,605.00 - 5,690.00|
|52 Week Range||5,605.00 - 8,110.43|
|PE Ratio (TTM)||6.54|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Feb.19 -- Rakesh Kapoor, chief executive officer at Reckitt Benckiser, discusses his outlook for the company for 2018, M&A prospects, valuations, the share price and advertising on social media. He speaks on "Bloomberg Markets: European Open."
Reckitt Benckiser Group plc (LSE:RB.) outperformed the Household Products industry on the basis of its ROE – producing a higher 25.00% relative to the peer average of 18.62% over theRead More...
Reckitt Benckiser has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said, even though there are concerns it may now be too stretched to buy Pfizer's coveted consumer health business. The Pfizer business, which is currently on the block, would fulfil Reckitt CEO Rakesh Kapoor's long-stated plan to transform Reckitt from a British maker of household cleaning products into a global leader in consumer healthcare.
Consumer staples companies such as Reckitt Benckiser Group Plc and Procter & Gamble Co. should be paying higher dividends to compensate investors for increasing levels of risk, according to the head of ...
Reckitt Benckiser (RB.L) has no regrets about its $17 billion (12.3 billion pounds) acquisition of Mead Johnson last year, its chief executive said, even though there are concerns it may now be too stretched to buy Pfizer's (PFE.N) coveted consumer health business. The Pfizer business, which is currently on the block, would fulfil Reckitt CEO Rakesh Kapoor's long-stated plan to transform Reckitt from a British maker of household cleaning products into a global leader in consumer healthcare.
McCormick (MKC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
European stocks fell in light holiday trading Monday while Asian bourses continued to rebound from an early February correction.
The FTSE (.FTSE) index ended the session flat at 7,246.77 points, lagging a broadly positive European market, while Britain's mid-cap index (.FTMC) added 0.8 percent, helped by news of a possible bid for software firm Fidessa. HSBC (HSBA.L) fell 3 percent after Europe's biggest lender by market value reported a jump in annual pre-tax profit that missed expectations and unveiled a plan to raise up to $7 billion over the next four months to bolster its capital base. Investec analysts confirmed their "neutral" rating on the stock, saying results were "all-in-all disappointing" and the absence of a share buyback was a negative surprise.
U.K.’s blue-chip stocks finish in the red Monday after last week’s strong performance, with losses for consumer-goods heavyweight Reckitt Benckiser Group PLC pressuring the London market’s benchmark.
European stocks close lower Monday, dragged down in part by falls for consumer products heavyweight Reckitt Benckiser Group PLC and German auto maker Daimler AG.
British shares lost some ground on Monday as weak results from Reckitt Benckiser (RB.L) underlined the murky growth outlook for big consumer goods makers and banking holidays in the U.S. and China slowed European markets. The UK's top share index (.FTSE) closed down 0.64 percent at 7,247.66 points, a decline broadly in line with other European bourses. "Investors knew market volatility would be low as the U.S. and Canada celebrate public holidays, and that weighed on enthusiasm," said David Madden, an analyst at CMC Markets.
By Danilo Masoni MILAN (Reuters) - European shares dipped in choppy trade on Monday as a poor update from Reckitt Benckiser (RB.L) hit consumer staples, though steel-makers rose after the United States ...
Reckitt Benckiser's shares sank after the British consumer goods group missed 2017 profit estimates, while tough trading conditions and rising commodity costs hit its outlook. Another factor weighing on Reckitt's shares was the heightened expectation of it buying the consumer health business being sold by Pfizer, which could potentially dilute shareholders through an equity capital increase. Reckitt's shares were down more than 7 percent at 1614 GMT in the biggest fall by a European blue-chip stock.
As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean.
European shares fell after Chinese markets remained closed overnight and the U.S. market is due to take a break for President’s Day.
Rakesh Kapoor, chief executive officer at Reckitt Benckiser, discusses his outlook for the company for 2018, M&A prospects, valuations, the share price and advertising on social media. He speaks on "Bloomberg ...
After a cyberattack and a botched product launch spoiled Reckitt Benckiser Group Plc’s 2017, a pricing squeeze threatens to make this year almost as tough.